---
document_datetime: 2025-09-30 09:33:08
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/usrenty-epar-all-authorised-presentations_en.pdf
document_name: usrenty-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.9644471
conversion_datetime: 2025-12-22 12:16:22.713194
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form                   | Route of Administration   | Immediate Packaging        | Content (concentration)   | Pack size            |
|------------------|-------------------|------------|---------------------------------------|---------------------------|----------------------------|---------------------------|----------------------|
| EU/1/25/1973/001 | Usrenty           | 45 mg      | Solution for injection                | Subcutaneous use          | vial (glass)               | 0.5 ml (90 mg/ml)         | 1 vial               |
| EU/1/25/1973/002 | Usrenty           | 45 mg      | Solution for injection                | Subcutaneous use          | pre-filled syringe (glass) | 0.5 ml (90 mg/ml)         | 1 pre-filled syringe |
| EU/1/25/1973/003 | Usrenty           | 90 mg      | Solution for injection                | Subcutaneous use          | pre-filled syringe (glass) | 1 ml (90 mg/ml)           | 1 pre-filled syringe |
| EU/1/25/1973/004 | Usrenty           | 130 mg     | Concentrate for solution for infusion | Intravenous use           | vial (glass)               | 26 ml (5 mg/ml)           | 1 vial               |